Nerve conduction and excitability studies in peripheral nerve disorders

Current Opinion in Neurology

Volumn 22, Issue 5, 2009, Pages 460-466

  Krarup, Christian ^a,b   Moldovan, Mihai ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Axonal degeneration; Compound muscle action potential; Compound sensory action potential; Demyelination; Ion channel dysfunction; Membrane depolarization; Nerve conduction studies; Nerve excitability

Indexed keywords

MYELIN; OXALIPLATIN; SODIUM CHANNEL;

CHANNELOPATHY; COLORECTAL CANCER; HUMAN; MEMBRANE DEPOLARIZATION; MUSCLE ACTION POTENTIAL; MUSCLE CRAMP; NERVE CONDUCTION; NERVE EXCITABILITY; NEUROTOXICITY; PARESTHESIA; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; REVIEW; UREMIA;

ACTION POTENTIALS; AXONS; DEMYELINATING DISEASES; DIAGNOSTIC TECHNIQUES, NEUROLOGICAL; HUMANS; NERVE DEGENERATION; NEURAL CONDUCTION; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 70349696654     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283304c9d     Document Type: Review

References (91)

1. Albers JW, Kelly JJ. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve 1989; 12:435-451.
2. Ho TW, Li CY, Cornblath DR, et al. Patterns of recovery in the Guillain-Barré syndromes. Neurology 1997; 48:695-700.
3. Tankisi H, Pugdahl K, Fuglsang-Frederiksen A, et al. Pathophysiology inferred from electrodiagnostic nerve tests and classification of polyneuropathies. Suggested guidelines. Clin Neurophysiol 2005; 116:1571-1580.
4. Shy ME, Jani A, Krajewski K, et al. Phenotypic clustering in MPZ mutations. Brain 2004; 127:371-384.
5. Nave KA, Trapp BD. Axon-glial signaling and the glial support of axon function. Annu Rev Neurosci 2008; 31:535-561.
6. Dyck PJ, Johnson WJ, Lambert EH, et al. Segmental demyelination secondary to axonal degeneration in uremic neuropathy. Mayo Clin Proc 1971; 46:400-431.
7. Buchthal F, Behse F. Peroneal muscular atrophy (PMA) and related disorders. I. Clinical manifestations as related to biopsy findings, nerve conduction and electromyography. Brain 1977; 100:41-66.
8. Birouk N, Gouider R, Le Guern E, et al. Charcot-Marie-Tooth disease type 1A with 17p11.2 duplication. Clinical and electrophysiological phenotype study and factors influencing disease severity in 119 cases. Brain 1997; 120:813-823.
9. Kaku DA, Parry GJ, Malamut R, et al. Nerve conduction studies in Charcot- Marie-Tooth polyneuropathy associated with a segmental duplication of chromosome 17. Neurology 1993; 43:1806-1808.
10. Mansouri B, Adybeig B, Rayegani M, et al. Uremic neuropathy and the analysis of electrophysiological changes. Electromyogr Clin Neurophysiol 2001; 41: 107-115.
11. Nielsen VK. The peripheral nerve function in chronic renal failure. A survey. Acta Med Scand 1974; Suppl. 573:1-32.
12. Stys PK, Ashby P. An automated technique for measuring the recovery cycle of human nerves. Muscle Nerve 1990; 13:750-758.
13. Tackmann W, Ullerich D, Cremer W, et al. Nerve conduction studies during the relative refractory period in sural nerves of patients with uremia. Eur Neurol 1974; 12:331-339.
14. Boë rio D, Hogrel JY, Creange A, et al. A reappraisal of various methods for measuring motor nerve refractory period in humans. Clin Neurophysiol 2005; 116:969-976.
15. Bergmans J. Physiological observations on single human nerve fibers. In: Desmedt JE, editor. New developments in electromyography and clinical neurophysiology. Basel: Karger; 1973. pp. 89-127.
16. Bergmans J. The Physiology of single human nerve fibres. University of Louvain, Belgium: Vander; 1970. pp. 1-320.
17. Bostock H, Grafe P. Activity-dependent excitability changes in normal and demyelinated rat spinal root axons. J Physiol 1985; 365:239-257.
18. Baker M, Bostock H. Depolarization changes the mechanism of accommodation in rat and human motor axons. J Physiol 1989; 411:545-561.
19. Baker M, Bostock H, Grafe P, et al. Function and distribution of three types of rectifying channel in rat spinal root myelinated axons. J Physiol 1987; 383:45-67.
20. Bostock H, Baker M. Evidence for two types of potassium channel in human motor axons in vivo. Brain Res 1988; 462:354-358.
21. Bostock H, Cikurel K, Burke D. Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve 1998; 21:137-158.
22. Burke D, Kiernan MC, Bostock H. Excitability of human axons. Clin Neurophysiol 2001; 112:1575-1585.
23. Nodera H, Kaji R. Nerve excitability testing and its clinical application to neuromuscular diseases. Clin Neurophysiol 2006; 117:1902-1916.
24. Kiernan MC, Burke D, Andersen KV, et al. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve 2000; 23:399-409.
25. Vizoso AD, Young JZ. Internode length and fibre diameter in developing and regenerating nerves. J Anat 1948; 82:110-134.
26. Berry CM, Grundfest H, Hinsey JC. The electrical activity of regenerating nerves in the cat. J Neurophysiol 1944; 7:103-115.
27. Querfurth HW, Armstrong R, Herndon RM. Sodium channels in normal and regenerated feline ventral spinal roots. J Neurosci 1987; 7:1705-1716.
28. Kocsis JD, Waxman SG. Long-term regenerated nerve fibres retain sensitivity to potassium channel blocking agents. Nature 1983; 304:640-642.
29. Moldovan M, Krarup C. Internodal function in normal and regenerated mammalian axons. Acta Physiol (Oxf) 2007; 189:191-200.
30. Moldovan M, Krarup C. Mechanisms of hyperpolarization in regenerated mature motor axons in cat. J Physiol 2004; 560:807-819. (Pubitemid 39530119)
31. Moldovan M. Recovery of excitability of peripheral motor axons during long term regeneration. In vivo electrophysiological study. Copenhagen: Copenhagen University; 2004; pp. 1-92.
32. Nakata M, Baba H, Kanai K, et al. Changes in Na+ channel expression and nodal persistent Na+ currents associated with peripheral nerve regeneration in mice. Muscle Nerve 2008; 37:721-730.
33. Moldovan M, Krarup C. Membrane function of regenerated axons in mouse [abstract]. J Neurol 2005; 252:49.
34. Sawai S, Kanai K, Nakata M, et al. Changes in excitability properties associated with axonal regeneration in human neuropathy and mouse Wallerian degeneration. Clin Neurophysiol 2008; 119:1097-1105.
35. Kanai K, Kuwabara S, Misawa S, et al. Altered axonal excitability properties in amyotrophic lateral sclerosis: impaired potassium channel function related to disease stage. Brain 2006; 129:953-962.
36. Moldovan M, Alvarez S, Krarup C. Motor axon excitability during Wallerian degeneration. Brain 2009; 132:511-523.
37. Behse F, Buchthal F, Carlsen F. Nerve biopsy and conduction studies in diabetic neuropathy. J Neurol Neurosurg Psychiatry 1977; 40:1072-1082.
38. Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes 1997; 46 (Suppl 2):S54-S57.
39. Brismar T, Sima AA, Greene DA. Reversible and irreversible nodal dysfunction in diabetic neuropathy. Ann Neurol 1987; 21:504-507.
40. Horowitz SH, Ginsberg-Fellner F. Ischemia and sensory nerve conduction in diabetes mellitus. Neurology 1979; 29:695-704.
41. Strupp M, Bostock H, Weigl P, et al. Is resistance to ischaemia of motor axons in diabetic subjects due to membrane depolarization? J Neurol Sci 1990; 99:271-280.
42. Weigl P, Bostock H, Franz P, et al. Threshold tracking provides a rapid indication of ischaemic resistance in motor axons of diabetic subjects. Electroencephalogr Clin Neurophysiol 1989; 73:369-371.
43. Kuwabara S, Ogawara K, Harrori T, et al. The acute effects of glycemic control on axonal excitability in human diabetic nerves. Intern Med 2002; 41:360-365.
44. Krishnan AV, Kiernan MC. Altered nerve excitability properties in established diabetic neuropathy. Brain 2005; 128:1178-1187.
45. Ng K, Lin CS, Murray NM, et al. Conduction and excitability properties of peripheral nerves in end-stage liver disease. Muscle Nerve 2007; 35:730-738.
46. Tan SV, Lee PJ, Walters RJ, et al. Evidence for motor axon depolarization in Fabry disease. Muscle Nerve 2005; 32:548-551.
47. Kiernan MC, Walters RJ, Andersen KV, et al. Nerve excitability changes in chronic renal failure indicate membrane depolarization due to hyperkalaemia. Brain 2002; 125:1366-1378.
48. Krishnan AV, Phoon RK, Pussell BA, et al. Altered motor nerve excitability in end-stage kidney disease. Brain 2005; 128:2164-2174.
49. Krishnan AV, Kiernan MC. Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve 2007; 35:273-290.
50. Bostock H, Walters RJ, Andersen KV, et al. Has potassium been prematurely discarded as a contributing factor to the development of uraemic neuropathy? Nephrol Dial Transplant 2004; 19:1054-1057.
51. Kuwabara S, Kanai K, Sung J-Y, et al. Axonal hyperpolarization associated with acute hypokalemia: multiple excitability measurements as indicators of the membrane potential of human axons. Muscle Nerve 2002; 26:283-287.
52. Kuwabara S, Misawa S, Kanai K, et al. The effects of physiological fluctuation of serum potassium levels on excitability properties in healthy human motor axons. Clin Neurophysiol 2007; 118:278-282.
53. Z'Graggen WJ, Lin CS, Howard RS, et al. Nerve excitability changes in critical illness polyneuropathy. Brain 2006; 129:2461-2470.
54. Evidente VGH, Gwinn-Hardy KA, Caviness JN, et al. Hereditary ataxias. Mayo Clin Proc 2000; 75:475-490.
55. Maylie B, Bissonnette E, Virk M, et al. Episodic ataxia type 1 mutations in the human Kv1.1 potassium channel alter hKvbeta 1-induced N-type inactivation. J Neurosci 2002; 22:4786-4793.
56. Wuttke TV, Jurkat-Rott K, Paulus W, et al. Peripheral nerve hyperexcitability due to dominant-negative KCNQ2 mutations. Neurology 2007; 69:2045-2053.
57. Schwarz JR, Glassmeier G, Cooper EC, et al. KCNQ channels mediate IKs, a slow K+ current regulating excitability in the rat node of Ranvier. J Physiol 2006; 573:17-34.
58. Newsom-Davis J. Autoimmune neuromyotonia (Isaacs' syndrome): an antibody- mediated potassium channelopathy. Ann N Y Acad Sci 1997; 835: 111-119.
59. Kiernan MC, Hart IK, Bostock H. Excitability properties of motor axons in patients with spontaneous motor unit activity. J Neurol Neurosurg Psychiatry 2001; 70:56-64. (Pubitemid 32096121)
60. Krishnan AV, Bostock H, Ip J, et al. Axonal function in a family with episodic ataxia type 2 due to a novel mutation. J Neurol 2008; 255:750-755.
61. Flink MT, Atchison WD. Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies. J Bioenerg Biomembr 2003; 35:697-718.
62. Missiaen L, Robberecht W, Van Den BL, et al. Abnormal intracellular ca(2+)homeostasis and disease. Cell Calcium 2000; 28:1-21.
63. Meisler MH, Kearney JA. Sodium channel mutations in epilepsy and other neurological disorders. J Clin Invest 2005; 115:2010-2017.
64. Kiernan MC, Krishnan AV, Lin CS, et al. Mutation in the Na+ channel subunit SCN1B produces paradoxical changes in peripheral nerve excitability. Brain 2005; 128:1841-1846.
65. Kiernan MC, Isbister GK, Lin CS, et al. Acute tetrodotoxin-induced neurotoxicity after ingestion of puffer fish. Ann Neurol 2005; 57:339-348.
66. Krarup-Hansen A, Rietz B, Krarup C, et al. Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy study. Neuropathol Appl Neurobiol 1999; 25: 29-40.
67. Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, et al. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 2007; 130:1076-1088.
68. Alaedini A, Xiang Z, Kim H, et al. Up-regulation of apoptosis and regeneration genes in the dorsal root ganglia during cisplatin treatment. Exp Neurol 2008; 210:368-374.
69. McDonald ES, Randon KR, Knight A, et al. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis 2005; 18:305-313.
70. Dzagnidze A, Katsarava Z, Makhalova J, et al. Repair capacity for platinum- DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J Neurosci 2007; 27:9451-9457.
71. Rodriguez-Menendez V, Gilardini A, Bossi M, et al. Valproate protective effects on cisplatin-induced peripheral neuropathy: an in vitro and in vivo study. Anticancer Res 2008; 28:335-342.
72. Albers J, Chaudhry V, Cavaletti G, et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2007;CD005228.
73. Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 2002; 29:11-20.
74. Kiernan MC. The pain with platinum: oxaliplatin and neuropathy. Eur J Cancer 2007; 43:2631-2633.
75. Wilson RH, Lehky T, Thomas RR, et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002; 20:1767-1774.
76. Krishnan AV, Lin CS, Park SB, et al. Assessment of nerve excitability in toxic and metabolic neuropathies. J Peripher Nerv Syst 2008; 13:7-26.
77. Krishnan AV, Goldstein D, Friedlander M, et al. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 2005; 32:51-60.
78. Park SB, Goldstein D, Lin CS, et al. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol 2009; 6:1243-1249.
79. Isbister GK, Kiernan MC. Neurotoxic marine poisoning. Lancet Neurol 2005; 4:219-228.
80. Yuki N, Kuwabara S. Axonal Guillain-Barre syndrome: carbohydrate mimicry and pathophysiology. J Peripher Nerv Syst 2007; 12:238-249. (Pubitemid 350179489)
81. Kuwabara S, Ogawara K, Sung J-Y, et al. Differences in membrane properties of axonal and demyelinating Guillain-Barré syndromes. Ann Neurol 2002; 52:180-187.
82. Kuwabara S, Bostock H, Ogawara K, et al. The refractory period of transmission is impaired in axonal Guillain-Barre syndrome. Muscle Nerve 2003; 28:683-689.
83. Kaji R, Nodera H. Who is the primary suspect in acute motor axonal neuropathy? Muscle Nerve 2003; 28:657-658.
84. Meulstee J, Darbas A, van Doorn PA, et al. Decreased electrical excitability of peripheral nerves in demyelinating polyneuropathies. J Neurol Neurosurg Psychiatry 1997; 62:398-400.
85. Cappelen-Smith C, Kuwabara S, Lin CS, et al. Membrane properties in chronic inflammatory demyelinating polyneuropathy. Brain 2001; 124:2439-2447.
86. Sung J-Y, Kuwabara S, Kaji R, et al. Threshold electrotonus in chronic inflammatory demyelinating polyneuropathy: correlation with clinical profiles. Muscle Nerve 2004; 29:28-37.
87. Nodera H, Bostock H, Kuwabara S, et al. Nerve excitability properties in Charcot-Marie-Tooth disease type 1A. Brain 2004; 127:203-211.
88. Krarup C, Stewart JD, Sumner AJ, et al. A syndrome of asymmetric limb weakness with motor conduction block. Neurology 1990; 40:118-127.
89. Kaji R. Physiology of conduction block in multifocal motor neuropathy and other demyelinating neuropathies. Muscle Nerve 2003; 27:285-296.
90. Lewis RA. Neuropathies associated with conduction block. Curr Opin Neurol 2007; 20:525-530.
91. Kiernan MC, Guglielmi JM, Kaji R, et al. Evidence for axonal membrane hyperpolarization in multifocal motor neuropathy with conduction block. Brain 2002; 125:664-675.